Newsroom 2005
- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has filed a short form preliminary prospectus with
the Canadian securities regulators and a registration statement with the U.S. Securities and Exchange Commission in
connection with an offering of 4,000,000 common shares. The offering will consist of a new issue of common shares.
UBS Investment Bank will be acting as the sole book running underwriter in this offering, and CIBC World Markets Inc.,
Piper Jaffray, Desjardins Securities Inc. and Wells Fargo Securities will be acting as co-managers. When available, copies
of the preliminary prospectus may be obtained from UBS Investment Bank, Prospectus Department, 299 Park Avenue,
New York, NY 10171 or 1010 Sherbrooke Street West, suite 2510, Montreal, Quebec, H3A 2R7.
Neurochem Inc. and its subsidiaries (Neurochem) intend to use the net proceeds from the offering to fund Neurochem's
clinical trials of its investigational product candidates, primarily Alzhemed™, as well as to further complete
pre-clinical and research and development programs and the balance for the marketing of Fibrillex™, working
capital and general corporate purposes.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission,
but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the
time the registration statement becomes effective. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of the securities in any state in which such offer,
solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such State.
About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying, oral products addresses critical, unmet medical needs.
1,3- propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug and a Fast Track Product candidate
and is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was recently concluded and the study data are expected to be
released in the second quarter of 2005. 3-amino-1-propanesulfonic acid (3APS; Alzhemed™), for the treatment of
Alzheimer's Disease, is in a Phase III clinical trial and 3APS; Cerebril™, for the prevention of Hemorrhagic
Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem Inc.'s control. The risks include but are not limited to: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem Inc. does business, stock market volatility, fluctuations in costs, and changes
to the competitive environment due to consolidation, as well as other risks disclosed in public filings of Neurochem
Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance on, if any, the forward-looking statements
included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no
obligation and disavows any intention to update or revise such statements as a result of any event, circumstances
or otherwise.
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
